737 related articles for article (PubMed ID: 23700882)
1. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
Irimia R; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
[TBL] [Abstract][Full Text] [Related]
2. Update on management of patients with overt hepatic encephalopathy.
Chacko KR; Sigal SH
Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
[TBL] [Abstract][Full Text] [Related]
4. Durability of rifaximin response in hepatic encephalopathy.
Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
[TBL] [Abstract][Full Text] [Related]
5. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.
Sanyal A; Younossi ZM; Bass NM; Mullen KD; Poordad F; Brown RS; Vemuru RP; Mazen Jamal M; Huang S; Merchant K; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2011 Oct; 34(8):853-61. PubMed ID: 21848797
[TBL] [Abstract][Full Text] [Related]
6. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.
Sharma P; Sharma BC; Agrawal A; Sarin SK
J Gastroenterol Hepatol; 2012 Aug; 27(8):1329-35. PubMed ID: 22606978
[TBL] [Abstract][Full Text] [Related]
7. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
Ahire K; Sonawale A
J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
[TBL] [Abstract][Full Text] [Related]
9. Management of hepatic encephalopathy in the hospital.
Leise MD; Poterucha JJ; Kamath PS; Kim WR
Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
[TBL] [Abstract][Full Text] [Related]
10. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.
Agrawal A; Sharma BC; Sharma P; Sarin SK
Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.
Sanyal AJ; Kowdley KV; Reau NS; Pyrsopoulos NT; Allen C; Heimanson Z; Bajaj JS
Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38727685
[TBL] [Abstract][Full Text] [Related]
12. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.
Leevy CB; Phillips JA
Dig Dis Sci; 2007 Mar; 52(3):737-41. PubMed ID: 17245628
[TBL] [Abstract][Full Text] [Related]
13. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.
Neff GW; Kemmer N; Zacharias VC; Kaiser T; Duncan C; McHenry R; Jonas M; Novick D; Williamson C; Hess K; Thomas M; Buell J
Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin treatment in hepatic encephalopathy.
Bass NM; Mullen KD; Sanyal A; Poordad F; Neff G; Leevy CB; Sigal S; Sheikh MY; Beavers K; Frederick T; Teperman L; Hillebrand D; Huang S; Merchant K; Shaw A; Bortey E; Forbes WP
N Engl J Med; 2010 Mar; 362(12):1071-81. PubMed ID: 20335583
[TBL] [Abstract][Full Text] [Related]
15. Optimal treatment of hepatic encephalopathy.
Waghray A; Waghray N; Kanna S; Mullen K
Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
[TBL] [Abstract][Full Text] [Related]
16. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.
Sharma BC; Sharma P; Agrawal A; Sarin SK
Gastroenterology; 2009 Sep; 137(3):885-91, 891.e1. PubMed ID: 19501587
[TBL] [Abstract][Full Text] [Related]
17. Rifaximin for treatment of hepatic encephalopathy.
Maclayton DO; Eaton-Maxwell A
Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
Huang E; Esrailian E; Spiegel BM
Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
[TBL] [Abstract][Full Text] [Related]
19. Rifaximin: new therapeutic indication and future directions.
Rivkin A; Gim S
Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin for the treatment of hepatic encephalopathy.
Mantry PS; Munsaf S
Transplant Proc; 2010 Dec; 42(10):4543-7. PubMed ID: 21168733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]